Drugs / KK2269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06266299 | Jan 2024 → Mar 2029 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, metastatic neoplasm +1 | Kyowa Kirin, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK2269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06266299 ↗ |
| Route | Intravenous | “KK2269 administered intravenously” NCT06266299 ↗ |